anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clinical studies of fentanyl transdermal system did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Data from intravenous studies with fentanyl suggest that the elderly patients may have reduced clearance and a prolonged half-life. Moreover, elderly patients may be more sensitive to the active substance than younger patients. A study conducted with the fentanyl transdermal system in elderly patients demonstrated that fentanyl pharmacokinetics did not differ significantly from young adult subjects, although peak serum concentrations tended to be lower and mean half-life values were prolonged to approximately 34 hours [see Clinical Pharmacology (12.3)].

Monitor geriatric patients closely for signs of sedation and respiratory depression, particularly when initiating therapy with fentanyl transdermal system and when given in conjunction with other drugs that depress respiration [see Warnings and Precautions (5.2)(5.4)].
An automated sterile compounding dose preparation station is disclosed herein. The preparation station determines availability data based on a current working status and queued dose orders and transmits the availability data to an application server. The preparation station receives, from the application server, an inventory dose order that does not correspond to a patient when the application server determines the automated sterile compounding dose preparation station has availability based on the availability date. The inventory dose order specifies a sterile compounded medication product that is suitable for administration by intravenous introduction to a human. The preparation station prepares an inventory dose corresponding to the inventory dose order, determines an expiration date of the inventory dose, and causes a printer to print a label for the inventory dose. The label indicates that the inventory dose is to be stored and includes information indicative of the expiration date of the inventory dose.
Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =\< 60 years old, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Aging is accompanied by a loss of muscle mass and strength. Because muscle strength is associated with functional performance in elderly individuals, various tasks of daily living is hampered by the overall decline. The consequence is a vicious circle, where inactivity caused by reduced functional capacity accelerates the loss of muscle mass, strength and physical function. The Short Physical Performance Battery (SPPB) is commonly used to assess functional capacity, where individuals with a score of 10 or less out of maximum 12 may be categorized as pre-frail. Because small-to-moderate limitations in functional status assessed by SPPB is associated with higher odds of losing future mobility, these individuals represent a group of great interest. Strategies to improve functional capacity in this population are therefore important. It is established that heavy-load strength training, alone or in combination with protein supplementation, can improve muscle mass, strength, and function in elderly individuals. However, most studies have focused on healthy older adults, and less is known about the effects of heavy-load strength training in pre-frail elderly individuals. Moreover, the extent to which training-induced gains in muscle mass and size are related to improvements in strength and functional capacity is still poorly understood, because few intervention studies in this population have quantified hypertrophy precisely. Hence, the aim of this study is to investigate the effects of 10 weeks of heavy load strength training, performed three times per week, on muscle mass (DXA scan), muscle thickness (ultrasound), muscle strength (dynamic and isometric), rate of force development, chair rise ability, and gait velocity. Participants are randomized to a group performing three weekly sessions of heavy-load strength training or a control group. In addition, to optimize gains in muscle mass and strength, the strength training group will receive daily protein supplementation throughout the intervention period. The investigators hypothesize that the intervention will improve muscle mass, muscle thickness and strength, and that improvements in muscle strength and rate of force development will be correlated with improvements in functional capacity.
PURPOSE:To provide an agent for inducing production of nitrogen oxide, capable of inducing the production of nitrogen oxide in living body or cultured cell and effective as an antitumor agent or a therapeutic agent for infectious diseases. CONSTITUTION:The objective agent for inducing the production of nitrogen oxide contains human interleukin 6 (human IL-6) as an active component and preferably further about 10-100 pts.wt. (based on 100 pts.wt. of IL-6) of a lipopolysaccharide(LPS) as another active component. The progression of the symptom of tumor can be suppressed by the local administration of the agent to a tumor to which a nitrogen oxide is expected to be effective and, further, the agent is effective for the treatment of various infectious diseases by the stimulation of the phagocytotic action of macrophage. Nitrogen oxides having various applications and represented by NO, NO2<->, NO3<-> and nitrosothioproline having pharmacological action as a vascular smooth muscle relaxation factor can be produced by cluturing macrophage in the presence of IL-6 or IL-6 and LPS.
The invention belongs to the field of gene engineering vaccines, and concretely relates to an eimeria tenella gametophyte antigen gene, expression and application of an expression product. The size of the open reading frame of the gene is 1617 bp, and the nucleotide sequence of the gene is shown as SEQ ID NO. 1. A prokaryotic expression vector pET28a-Etgam59 is constructed based on the gene, and is transformed into BL21 host bacterium for inducible expression. The expression product can be recognized by chicken convalescent serum, which shows that recombinant protein possesses immunogenicity. The obtained serum of an immunized mouse of a recombinant eukaryotic expression plasmid pcDNA3.1-Etgam59 constructed by amplifying the gene is capable of specifically combined with the expression product of pET28a-Etgam59, which shows that the gene is applicable to development of a chicken coccidiosis gene engineering vaccine.
An oral hygiene system includes a probe for use as a clinical measuring instrument or gauge. The probe is adapted for assessing the degree of inflamation of various animal tissues. One embodiment of the probe is useful for examination of periodontal tissues, particularly the determination of pocket depths and the degree of gingivitis. The probe has a needle member affixed orthogonally to one end of its head, and the other end of the head mounts in a handle. Between the two ends of the head there are thin resilient members adapted for transmitting an appropriate force to the tip of the needle during measurement of the depth of the pocket. Another needle member has upper and lower ends. At the lower end, there is a hemispherical tip having an angular bevel facing toward the upper end of the needle so as to form an equatorial rim about the tip. There are calibration marks extending from the tip of the needle.
Iatrogenic injuries to the circumflex coronary artery during mitral valve surgery are probably underestimated (reported rates of 0.3-1.8%). This complication arises from the artery's close proximity to the mitral annulus, particularly at the anterolateral commissure. The study aimed to assess this risk in a patient group prone to such injury. The surgical procedure utilized a minimally invasive approach and indocyanine green-based fluorescence imaging. This technique allows a real-time visualization of the circumflex artery, aiding precise placement of annular sutures and minimizing the risk of injury. The method, applied in 6 patients, integrates preoperative assessments with intraoperative fluorescence imaging, ensuring accurate arterial depiction and preventing iatrogenic damage. The study highlights the safety and efficacy of fluorescence imaging, especially in identifying vessel anomalies, indicating potential applications in various cardiac procedures.
<P>PROBLEM TO BE SOLVED: To provide an immunological reagent used for treatments in radiation immunotherapy (RAIT) and immunochemotherapy and an immunological reagent used for detection and/or diagnosis in radiation-immunity detection (RAID), ultrasonic examination and magnetic resonance imaging (MRI).  <P>SOLUTION: A bi-specific antibody or antibody fragment having at least one arm able to react with a targeted tissue and at least one other arm able to react with a linker moiety is provided. The linker moiety contains a hapten in which an antibody is prepared. Such an antigenic linker is conjugated with one or more therapeutic agents, diagnostic agents or enzymes. A construct and a method for producing the bi-specific antibodies or antibody fragments are provided. A method for using the same is also provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Heterochromatin is critical for maintaining genome stability, especially in flowering plants, where it relies on a feedback loop involving the H3K9 methyltransferase, KRYPTONITE (KYP), and the DNA methyltransferase CHROMOMETHYLASE3 (CMT3). The H3K9 demethylase INCREASED IN BONSAI METHYLATION 1 (IBM1) counteracts the detrimental consequences of KYP-CMT3 activity in transcribed genes. IBM1 expression in Arabidopsis is uniquely regulated by methylation of the 7th intron, allowing it to monitor global H3K9me2 levels. We show the methylated intron is prevalent across flowering plants and its underlying sequence exhibits dynamic evolution. We also find extensive genetic and expression variations in KYP, CMT3, and IBM1 across flowering plants. We identify Arabidopsis accessions resembling weak ibm1 mutants and Brassicaceae species with reduced IBM1 expression or deletions. Evolution towards reduced IBM1 activity in some flowering plants could explain the frequent natural occurrence of diminished or lost CMT3 activity and loss of gene body DNA methylation, as cmt3 mutants in A. thaliana mitigate the deleterious effects of IBM1.
The present invention relates to a novel antibody binding to the RBD of the Spike protein of the SARS-CoV-2. The antibody recognizes a conformational epitope of the Spike RBD protein, inhibits Spike RBD - ACE2 binding, and inhibits viral infection in Virus Neutralization Test (VNT). The inhibition of the viral infection was observed for the wild-type SARS Cov-2 (variant B. 1.) as well as for the variant of concern (B. 1.1.7.) of the SARS CoV-2.The invention further provides the method for detecting and quantifying protective antibodies against the SARS Cov-2 Spike protein using the novel antibody.
Atrial fibrillation (AF) is highly prevalent in the Australian community, ranking amongst the highest globally. The consequences of AF are significant. Stroke, dementia and heart failure risk are increased substantially, hospitalisations are amongst the highest for all cardiovascular causes, and Australians living with AF suffer from substantial symptoms that impact quality of life. Australian research has made a significant impact at the global level in advancing the care of patients living with AF. However, new strategies are required to reduce the growing incidence of AF and its associated healthcare demand. The Australian Cardiovascular Alliance (ACvA) has led the development of an arrhythmia clinical theme with the objective of tackling major research priorities to achieve a reduction in AF burden across Australia. In this summary, we highlight these research priorities with particular focus on the strengths of Australian research and the strategies needed to move forward in reducing incident AF and improving outcomes for those who live with this chronic condition.
Storytelling Through Music is a six-week intervention that utilizes storytelling, reflective writing, self-care skills, and song-writing. The intervention will be administered in small groups of 4-6 participants/group and with a hybrid approach. The writing workshops will occur online, and the share circle (stories and songs shared with the group) will occur in person. The group sizes will be kept small to ensure that each participant has adequate time to share their writing during the group sessions.
A multi-center prospective cohort study will be conducted to explore the change trend of eosinophil in peritoneal dialysis effluent during peritoneal dialysis-associated peritonitis, and to explore the relationship between eosinophil increase, peritonitis severity and antibiotic use. In this study, 100 patients with peritoneal dialysis-associated peritonitis who meet the inclusion criteria will be selected. Demographic data, laboratory variables, peritoneal fluid cytology and bacterial culture will be collected within 24 hours of peritonitis (day 1). Peritoneal fluid cytology includes leukocyte classification and eosinophilic leukocyte count will be examined at day 3, 5, 7, 10, 14, 21, 30, 60 and 90 after peritonitis. All patients will be followed up for 90 days, and their peritonitis outcome will be recorded. The primary endpoint is the prevalence of eosinophil increase in peritoneal effluent, which is defined as \>100 eosinophils/mm\^3, or \>10% eosinophils of the total non-erythrocyte count. Secondary end points are peritonitis outcome at month 1 and 3 including transfer to hemodialysis , death.
Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with somatropin. Symptoms usually occurred within the first eight (8) weeks after the initiation of somatropin. In all reported cases, IH-associated signs and symptoms resolved rapidly after cessation of therapy or a reduction of the somatropin dose. Fundoscopic examination should be performed routinely before initiating treatment with ZOMACTON to exclude preexisting papilledema, and periodically thereafter. If papilledema is observed by fundoscopy, treatment should be stopped. If somatropin-induced IH is diagnosed, treatment with ZOMACTON can be restarted at a lower dose after IH-associated signs and symptoms have resolved. Patients with Turner syndrome may be at increased risk for the development of IH.
OBJECTIVES: The World Health Organization recommends the use of oral cholera vaccine (OCV) in cholera control efforts. Euvichol®, pre-qualified in 2015, is the leading component of the Global OCV stockpile, but data on its field effectiveness are limited. To evaluate Euvichol® vaccine effectiveness (VE), we conducted a case-control study between September 2018 to March 2020 following an OCV campaign in November 2017 in Haiti.
METHODS: Cases were individuals with acute watery diarrhea. Stool samples were tested by culture and real-time polymerase chain reaction of the Vibrio cholerae ctxA gene. Cases were matched to four community controls without diarrhea by residence, enrollment time, age, and gender, and interviewed for sociodemographics, risk factors, and self-reported vaccination. Cholera cases were analyzed by conditional logistic regression in the VE study. Non-cholera diarrhea cases were analyzed in a bias-indicator study.
RESULTS: We enrolled 15 cholera cases matched to 60 controls, and 63 non-cholera diarrhea cases matched to 249 controls. In the VE analysis, eight (53%) cases reported vaccination with any number of doses compared to 43 (72%) controls. Adjusted two-dose OCV VE was 69% (95% CI -71 to 94%).
CONCLUSIONS: Between 10-27 months after vaccination, Euvichol® was effective and similar to Shanchol™, suggesting that it can serve as one component of multi-sectoral comprehensive cholera control.
PROBLEM TO BE SOLVED: To prepare a therapeutic agent capable of rapidly reducing fungal and trichophytic dermal infectious diseases without any adverse effects by using a bamboo vinegar or a forest vinegar. SOLUTION: This therapeutic agent for fungal and trichophytic dermal and mucosal infectious diseases comprises a bamboo vinegar or a forest vinegar containing syringol, guaiacol and a derivative thereof as active ingredients. Propolis containing a flavonoid as an active ingredient is preferably further contained therein. The forest vinegar is obtained by adding a cellulase enzymic liquid to a pyroligneous acid, prepared by pyrolyzing (dry distilling) a tree bark of a laurel tree and having a smoking smell and carrying out the purification. The bamboo vinegar is obtained by dry distilling a bamboo. The propolis is extracted from a bee resin or a wasp resin with an alcohol.  Since the propolis, bamboo vinegar and forest vinegar are capable of manifesting growth inhibiting effects on Candisa albicans, Trichophyton mentagrophytes, etc., which are causative fungi of superficial dermal and mucosal infectious diseases for a human as an object, the ingredients are effectively used as the agent.
Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.
PURPOSE: Repair of midline ventral incisional hernias (VIHR) requires mesh reinforcement. Mesh types can be categorised into synthetic, biosynthetic, or biological. There is a lack of evidence to support one type of mesh over another. The aim of this pilot study was to compare mesh sensation in patients having undergone elective open repair with synthetic or biosynthetic mesh.
METHODS: Four years of prospectively collected data were retrospectively reviewed on 40 patients who had undergone VIHR, using either biosynthetic or synthetic mesh placed in the retromuscular plane. The decision on type of mesh used was governed by patient characteristics. Patients were invited to complete the Carolinas Comfort Scale (CCS) questionnaire, the higher the score indicating a poorer quality of life. The maximum length of follow-up was 36 months.
RESULTS: Twenty patients received permanent synthetic and 20 biosynthetic mesh. There was no clinical evidence of hernia recurrence in either group in the short to medium term. Overall, 97% (39/40) patients reported an average of either no or mild symptoms (mean CCS score 17.9 of 115). Patients with a biosynthetic repair had a significant lower CCS at ≥ 18 months (p < 0.05).
CONCLUSION: After VIHR, patients have low CCS scores, indicating good quality of life outcomes, in the short to medium term irrespective of the mesh used. However, biosynthetic mesh had lower CCS scores in the medium term. This may help surgeons and patients make better informed decisions about which mesh to use in their individual circumstances.
Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Subjects will be provided an Oculus Go VR headset pre-loaded with a "menu" of virtual reality programs which have been designed specifically to treat both acute and chronic pain. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
AIMS: Sudden cardiac death (SCD) may occur in apparently healthy individuals, including athletes. The aim was to investigate the diagnostic role of post-mortem genetic testing, molecular autopsy (MA), in elucidating the cause of SCD in athletes.
METHODS AND RESULTS: We reviewed a database of 6860 consecutive cases of SCD referred to our specialist cardiac pathology centre. All cases underwent detailed cardiac autopsy, and 748 were deemed to be athletes. Of these, 42 (6%) were investigated with MA (28 using a targeted sequencing, 14 exome sequencing). Variants were classified as pathogenic, likely pathogenic, or variant of unknown significance using international guidelines. Clinical information was obtained from referring coroners who completed a detailed health questionnaire. Out of the 42 decedents (average age 35 years old, 98% males) who were investigated with MA, the autopsy was in keeping with a structurally normal heart [sudden arrhythmic death syndrome (SADS)] in n = 33 (78%) cases, followed by arrhythmogenic cardiomyopathy (ACM) in eight (19%) individuals and idiopathic left ventricular fibrosis in one (2%). Death occurred during exercise and at rest in 26 (62%) and 16 (38%) individuals, respectively. Variants that were adjudicated clinically actionable were present in seven cases (17%). There was concordance between the genetic and phenotypic findings in two cases of ACM (in FLNC and TMEM43 genes). None of the variants identified in SADS cases were previously linked to channelopathies. Clinically actionable variants in cardiomyopathy-associated genes were found in five cases of SADS.
CONCLUSION: The yield of MA in athletes who died suddenly is 17%. In SADS cases, clinically actionable variants were found in cardiomyopathy-associated genes and not in channelopathy-associated genes. Arrhythmogenic cardiomyopathy is a common cause of SCD in athletes, and one in four decedents with this condition had a clinically actionable variant in FLNC and TMEM43 genes.